jetzt nur nichts schlecht reden nach dem Ausstieg;-) Glückwunsch zum Trade. Für mich aber aktuell zu risikoreich, da jederzeit über Nacht die Ergebnisse veröffentlicht werden können. Dann starten wir nicht bei 10USD sondern erstmal bei 14/15... Die Staaten kommen schon noch und werden anfragen.. Hier nochmal zu Cantor...
RedHill Biopharma initiated overweight at Cantor citing COVID-19 prospects
Aug. 31, 2021 1:08 PM ET RedHill Biopharma Ltd. (RDHL)
By: Dulan Lokuwithana, SA News Editor
Extending the rally into the fourth straight session, RedHill Biopharma (NASDAQ:RDHL) is set to post its second consecutive double-digit gain in percentage terms today after Cantor Fitzgerald initiated its coverage with an overweight rating.
On Monday, RedHill Biopharma (RDHL) reported positive Phase 2 data for the company’s experimental COVID-19 therapy Opaganib indicating that patients who received the oral therapy required less oxygen and were discharged earlier from the hospital compared to the placebo.
Cantor analyst, Brandon Folkes, identifies the company’s portfolio as “broad, deep and robust,” with two potential COVID-19 therapeutics. In addition, RedHill Biopharma’s (RDHL) commercial portfolio, “provides investors with a compelling investment opportunity given significant potential upside from current levels, even if only one or two projects from its pipeline are successful,” Folkes argued.
Cantor sets a $22 per share price target on the company to imply a premium of ~156.1% to the last close.
In addition to Opaganib, RedHill Biopharma (RDHL) is advancing its oral anti-viral RHB-107 (upamostat) in a Phase 2/3 study targeting symptomatic COVID-19 in non-hospitalized patients who don’t require supplemental oxygen. |